ELEV
Elevation Oncology, Inc.
Industry
Biotechnology
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Loading...
Open
0.63
Mkt cap
38M
Volume
768K
High
0.67
P/E Ratio
-0.80
52-wk high
5.83
Low
0.63
Div yield
N/A
52-wk low
0.44

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.